Resumen
Synthetic multiepitopic chimera as a vaccine and treatment against leishmaniasis in mammals. The invention relates to synthetic chimeras including 4 multiepitopic peptides against Leishmania. Each of the peptides has been selected from a Leishmania infantum protein. These are the nucleosomal histones H2A, H2B, H3 and H4. The invention also relates to a pharmaceutical composition that includes one of these synthetic chimeras. It also refers to a prophylactic and/or therapeutic vaccine against Leishmania spp for use in mammals and especially in humans and dogs. (Machine-translation by Google Translate, not legally binding)